A Prospective Clinical Trial of D–Penicillamine in the Treatment of Primary Biliary Cirrhosis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We conducted a prospective clinical trial to assess the relative efficacy and safety of high– vs. low–dose D–penicillamine in patients with primary biliary cirrhosis. Following clinical tests and liver biopsy diagnostic of primary biliary cirrhosis, 56 patients were randomized to receive either 250 or 750 mg D–penicillamine daily. Patients were monitored with clinical tests and annual liver biopsy. Randomization produced two groups without differences in demographic, clinical or histologic characteristics. During the trial, no differences were seen between the mean change in liver test results in patients in either treatment group. The 11% per year rise of bilirubin in the 750 mg dose group during the first 3 years was not significantly different from the 18% per year rise in the 250 mg dose group. No patient showed improvement on liver biopsy although patients on 750 mg D–penicillamine deteriorated more slowly. Side effects, particularly rash and dysgeusia, were more common in the 750 mg dose group. The frequency and severity of side effects were responsible for the early conclusion of our trial. Twenty–six patients experienced side effects necessitating discontinuation of D–penicillamine. No evidence of increased efficacy was demonstrated by high–dose D–penicillamine therapy, and side effects were observed in patients on 250 mg D–penicillamine daily. With the severity of adverse effects and continued progression of disease, D–penicillamine is not a clinically useful therapy in primary biliary cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 1×
“The clinical characteristics of our patients are delineated in Table 1 and are similar to those described in other large series (4, 5).”
Result
Cited by
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Metadata
- Authors
- Bodenheimer, H. C., Schaffner, F., Sternlieb, I., Klion, F. M., Vernace, S., & Pezzullo, J.
- Venue
- Hepatology
- Published
- 1985-11
- Volume
- 5
- Issue
- 6
- Pages
- 1139-1142
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2009221394
- Cited by
- 60
- References
- 1
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective Clinical Trial of D–Penicillamine in the Treatment of Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1002/hep.1840050613
- The paper
- Bodenheimer, H. C., Schaffner, F., Sternlieb, I., Klion, F. M., Vernace, S., & Pezzullo, J. (1985). A Prospective Clinical Trial of D–Penicillamine in the Treatment of Primary Biliary Cirrhosis. Hepatology. https://doi.org/10.1002/hep.1840050613
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.